Today's Daily Dose brings you news about results from Allergan's clinical study evaluating higher doses of BOTOX Cosmetic; CEL-SCI's better capitalization, following exercise of warrants; Kiniksa's phase 1a/1b clinical trial of KPL-716 in moderate-to-severe atopic dermatitis, and FDA approval of Teva's preventive treatment of migraine.
from RTT - Biotech https://ift.tt/2NhNAFe
via IFTTT
No comments:
Post a Comment